Fast Five Quiz: Type 2 Diabetes and Cardiovascular Disease Risk

Romesh Khardori, MD, PhD

Disclosures

January 14, 2021

Large randomized controlled trials have reported statistically significant reductions in cardiovascular events among patients receiving GLP-1 receptor agonists (liraglutide, semaglutide, and dulaglutide). In addition, statistically significant reductions in cardiovascular events have also been reported in trials for the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin.

Presently, cardiovascular outcomes trials of DPP-4 inhibitors have not shown cardiovascular benefits relative to placebo.

Among patients with T2D and established atherosclerotic CVD, multiple atherosclerotic CVD risk factors, or diabetic kidney disease, an SGLT2 inhibitor with demonstrated cardiovascular benefit is recommended to reduce the risk for major adverse cardiovascular events as well as heart failure hospitalization. For patients with T2D and established atherosclerotic CVD or multiple risk factors for atherosclerotic CVD, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended to reduce the risk for major adverse cardiovascular events.

DPP-4 inhibitors may lead to worsening heart failure in patients with established CVD or metabolic abnormalities.

Learn more about pharmacologic therapy for CVD risk reduction in patients with T2D.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....